DCs-CIK细胞免疫治疗联合化疗对转移性前列腺癌患者免疫功能及生活质量的影响

目的:探讨DCs-CIK细胞免疫(Dendritic cells-Cytokine induced killer cells,DCs-CIK)治疗联合化疗对转移性前列腺癌患者免疫功能及生活质量的影响。方法:选择106例确诊转移性前列腺癌患者随机分为观察组与对照组,每组各53例,对照组采用多西他赛联合表阿霉素~+泼尼松化疗方式进行治疗,观察组在此基础上给予DC-CIK细胞免疫治疗。比较两组患者治疗前后外周血CD3~+、CD3~+CD4~+、CD3~+CD8~+、CD3-CD56~+、CD4~+CD8~+、自然杀伤细胞(NK)、自然杀伤T细胞(NKT)表达水平;使用QLQ-C30问卷评价患者治疗前后生活质量的变化情况,观察并比较患者治疗过程中发生的不良反应情况。结果:组观察组患者治疗总有效率达73.58%远高于对照组41.51%水平(p0.05);观察组患者治疗后外周血CD3~+、CD3~+CD4~+、CD3~+CD8~+、CD3-CD56~+、CD4~+CD8~+、NK、NKT表达水平明显好于对照组(p0.05);观察组患者躯体功能、角色功能、情绪功能、认知功能、社会功能各项指标得分明显好于对照组(p0.05);两组患者接受治疗后,均有部分患者出现恶心呕吐、脱发、白细胞减少、血小板减少或肝功受损,其中观察组患者出现恶心呕吐、白细胞减少的人数明显少于对照组(p0.05)。结论:DCs-CIK细胞免疫治疗联合化疗有助于转移性前列腺癌患者的治疗,在明显改善患者免疫能力的同时有效改善患者生活质量,具有重要的临床指导意义。

Effect of the Quality of Life and Immune Function in Patients with Metastatic Prostate Cancer Treated by Chemotherapy Combined with DC-CIK Cell Treatment

ABSTRACT Objective: To explore the effect of biological immunotherapy plus chemotherapy on the Quality of life and immune function in patients with metastatic prostate cancer. Methods: 106 cases of metastatic prostate cancer patients were selected an randomly divided into observation group and control group, each with 53 cases. The control group was given pure chemotherapy scheme with Docetaxel plus Epirubicin and Prednisone, the observation group was given the same hemotherapy combined with DC-CIK cell treatment. The response of immune tissue cells in the Peripheral blood of CD3 ⁺, CD3 ⁺ CD4⁺, CD3 ⁺ CD8 ⁺, CD3^- CD56 ⁺, CD4⁺CD8⁺, NK and NKT of two groups were checked before and after treatment. The patients'' quality of life ( QOL) after chemotherapy in two groups were analyzed and compared with QLQ-C30 questionnaire, meanwhile adverse reactions occurred in patients during treatment were observed and compared between the two groups. Results: The total effective rate of the observation group was 73.58%, higher than that of the control group with 41.51%(p<0.05). The CD3 ⁺, CD3 ⁺ CD4⁺, CD3 ⁺ CD8 ⁺, CD3^- CD56⁺, CD4⁺CD8⁺, NK, NKT expression levels in observation group after treatment were significantly better than the control group (p<0.05); The scores of physical function, role function, emotional function, cognitive function and social function of the observation group were significantly better than those of the control group tested by QLQ-C30 questionnaire (p<0.05); after treatment, Nausea and vomiting, alopecia, leukopenia, thrombocytopenia or liver damage were observed in both groups, in which the number of adverse reactions in observation group was significantly less than the control group (p<0.05). Conclusion: DCs-CIK cell immunotherapy combined with chemotherapy is helpful in the treatment of metastatic prostate cancer, which has important clinical significance in improving the immune function of patient and the quality of life of patients.